Development of a genetically tailored implantation hepatocellular carcinoma model in Oncopigs by somatic cell CRISPR editing
Disease Models & Mechanisms · 01.01.2025 · 18 (1)
DOI: 10.1242/dmm.052079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, online erschienen am 29.01.2025. Verfasst von Lobna Elkhadragy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Illinois at Chicago, Chicago, IL 60612, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Gene Editing, Liver Neoplasms, CRISPR-Cas Systems. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH NCI, National Cancer Institute.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is an aggressive disease with poor prognosis, necessitating preclinical models for evaluating novel therapies. Large-animal models are particularly valuable for assessing locoregional therapies, which are widely employed across HCC stages. This study aimed to develop a large-animal HCC model with tailored tumor mutations. The Oncopig, a genetically engineered pig with inducible TP53R167H and KRASG12D, was used in the study. Hepatocytes were isolated from Oncopigs and exposed to Cre recombinase in vitro to create HCC cells, and additional mutations were introduced by CRISPR/Cas9 knockout of PTEN and CDKN2A. These edits increased Oncopig HCC cell proliferation and migration. Autologous HCC cells with these CRISPR edits were implanted into Oncopigs using two approaches: ultrasound-guided percutaneous liver injections, which resulted in the development of localized intrahepatic masses, and portal vein injections, which led to multifocal tumors that regressed over time. Tumors developed by both approaches harbored PTEN and CDKN2A knockout mutations. This study demonstrates the feasibility of developing genetically tailored HCC tumors in Oncopigs using somatic cell CRISPR editing and autologous implantation, providing a valuable large-animal model for in vivo therapeutic assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, University of Illinois at Chicago, Chicago, IL 60612, USA.
- Department of Pathology, University of Illinois at Chicago, Chicago, IL 60612, USA.
- Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Champaign, IL 61802, USA.
- Department of Animal Sciences, University of Illinois at Urbana-Champaign, Champaign, IL 61801, USA.
ORCID-Profile: Lobna Elkhadragy, Ron C Gaba
Förderung
- NCI NIH HHS
- NIH NCI
- National Cancer Institute
Zitieren
APA
Elkhadragy, L., Carlino, M. J., Jordan, L. R., Pennix, T., Ismail, N., Guzman, G., Samuelson, J. P., Schook, L. B., Schachtschneider, K. M., & Gaba, R. C. (2025). Development of a genetically tailored implantation hepatocellular carcinoma model in Oncopigs by somatic cell CRISPR editing. Disease Models & Mechanisms, 18(1). https://doi.org/10.1242/dmm.052079
Vancouver
Elkhadragy L, Carlino MJ, Jordan LR, Pennix T, Ismail N, Guzman G, et al. Development of a genetically tailored implantation hepatocellular carcinoma model in Oncopigs by somatic cell CRISPR editing. Disease Models & Mechanisms. 2025;18(1). doi:10.1242/dmm.052079
BibTeX
@article{Elkhadragy2025,
author = {Elkhadragy, Lobna and Carlino, Maximillian J and Jordan, Luke R and Pennix, Thomas and Ismail, Nahed and Guzman, Grace and Samuelson, Jonathan P and Schook, Lawrence B and Schachtschneider, Kyle M and Gaba, Ron C},
title = {Development of a genetically tailored implantation hepatocellular carcinoma model in Oncopigs by somatic cell CRISPR editing},
journal = {Disease Models & Mechanisms},
year = {2025},
volume = {18},
number = {1},
doi = {10.1242/dmm.052079}
}
EUVIMED